For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Methodist receives $25M gift, renames department of medicine

med funding

Houston-based nonprofit The Duncan Fund has awarded a $25 million gift to Houston Methodist's department of medicine to establish new endowed fellowships, streamline complex care and bring artificial intelligence into the fold to develop more personalized treatment plans.

In turn, the health care system announced that it will rename the department the Charles W. Duncan Jr. Department of Medicine at Houston Methodist.

“We are deeply appreciative of the Duncan family’s support, which allows us to further programs at the intersection of personalized medicine and preventive health care to benefit our patients,” Dr. Eleftherios Mylonakis, chair of the department and the Charles and Anne Duncan Presidential Distinguished Chair, said in a news release.

The department of medicine is Houston Methodist's largest, and comprises 13 clinical programs, ranging from general medicine to highly specialized care, as well as research and education.

According to Houston Methodist, the latest grant from the Duncan family will:
  • Coordinate complex, multidisciplinary care by hospitalists
  • Implement programs that leverage data and AI to tailor treatments and preventive strategies
  • Establish five endowed fellowships, including a new fellowship for students known as MedTech Innovator

“Our vision is to redefine how care is delivered in our country by creating a national model for true continuity — one that follows the patient across every transition, from home to hospital and back again,” Mylonakis added in the release. “We are also advancing a deeper understanding of health span, shifting from reactive treatment to a proactive, lifelong strategy that maximizes not just how long we live but how well we live.”

The Duncan family has been a longtime supporter of Houston Methodist—and Houston organizations at large. The late Charles Duncan Jr. sat on the system's board for decades, and his son, Charles “Carlos” Duncan III, serves on the Houston Methodist Hospital Foundation Board. Additionally, the family established the Charles and Anne Duncan Scholars Program and endowed chairs in nephrology and endocrinology.

Charles Duncan Jr. is also the namesake behind Rice University's Duncan Residential College and was one of the founders of the Greater Houston Partnership. He served as Secretary of Energy during the Carter Administration.

New York Stock Exchange Texas announces location for Dallas headquarters

NYSE Texas

A location has been chosen for The New York Stock Exchange Texas, the new Dallas-based offshoot of the The New York Stock Exchange in New York.

According to a release, the NYSE Texas has leased 28,000 square-feet of space at Old Parkland, the hospital-turned office space at 3819 Maple Ave. in Oak Lawn, where it will operate as a fully electronic equities exchange headquartered in Dallas. The property is owned by Dallas billionaire Harlan Crowe, who acquired it in 2006.

The NYSE is part of the Intercontinental Exchange, Inc., a global provider of technology and data. It was previously the NYSE Chicago, which will close once the bureau in Texas debuts.

They’ve also named a president to the Texas branch: Bryan Daniel, former chairman of the Texas Workforce Commission. In his new role over the NYSE Texas, Daniel will report to President of NYSE Group Lynn Martin.

Relocating from Chicago to Texas was a response to Texas' pro-business profile, Martin says in a statement.

“As the state with the largest number of NYSE listings, representing over $3.7 trillion in market value for our community, Texas is a market leader in fostering a pro-business atmosphere,” Martin says. “We are delighted to expand our presence in the Lone Star State, which plays a key role in driving our U.S. economy forward.”'

The move comes five months after the Texas Stock Exchange — AKA TXSE — announced plans to launch in Dallas and begin trading in 2026, pending approval from the U.S. Securities and Exchange Commission. The Texas Stock Exchange is backed by financial giants such as BlackRock, Citadel Securities, and Charles Schwab.

The NYSE expects the Texas location to open in 2026, where it will operate electronically, with stocks trading across multiple venues regardless of where they are first listed, according to the release.

---

This article originally appeared on CultureMap.com.